Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Lin, Liping; Zhao, Juanjuan; Hu, Jiazhu; Huang, Fuxi; Han, Jianjun; He, Yan; Cao, Xiaolong

Lin, Liping; Zhao, Juanjuan; Hu, Jiazhu; Huang, Fuxi; Han, Jianjun; He, Yan; Cao, Xiaolong.

Afiliação

Lin L; Department of Oncology, Panyu Central Hospital, Guangzhou, China.
Zhao J; Cancer Institute of Panyu, Guangzhou, China.
Hu J; School of Nursing, Sun Yat-sen University, Guangzhou, China.
Huang F; Department of Oncology, Panyu Central Hospital, Guangzhou, China.
Han J; Cancer Institute of Panyu, Guangzhou, China.
He Y; Department of Oncology, Panyu Central Hospital, Guangzhou, China.
Cao X; Cancer Institute of Panyu, Guangzhou, China.

J Cancer ; 9(3): 528-534, 2018.

Article em En | MEDLINE | ID: mdl-29483958

Palavras-chave

EGFR mutation; EGFR-tyrosine kinase inhibitors; Weight loss; non-small cell lung cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China País de publicação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google